

37°C in 0.1M EPPS, pH 7.5
x10⁴
23947.90
18278.46
496.73
L1-496
24444.63 L1
14546.46
23400 23600 23800 24000 24200 24400 24600 24800 25000 25200 25400 25600
496.97
496.60
496.64
H3-496*2
52794.61
25368.13
H3
52297.83
17375.81
H3-496*3
H3-496
53291.48
11472.97
51800.86
7484.22
51962.48
495.11
52459.90
2308.36
52956.57
3018.84
53453.51
1241.81
53761.50
1307.61
51600 52000 52400 52800 53200 53600 54000 54400
Counts vs. Deconvoluted Mass (amu)
4°C in 20 mM succinc acid, 8% sucrose,pH 5.5
24444.84
37397.73
L1
Counts vs. Deconvoluted Mass (amu)
53291.50
84107.46
4922.73
H3
H4
51845.68
1415.56
52794.78
8419.79
53453.66
11877.70
4214.23
964.45
Counts vs. Deconvoluted Mass (amu)

FIG. 1



LC
L1
1130.22
24652.75
39627.93
23522.32
91.88
1130.29
24652.73
35319.03
23522.44
56.78
452.96
24652.76
17091.47
24199.83
5518.02
Counts vs. Deconvoluted Mass (amu)

FIG. 2A



HC
H3
53915.13
59266.61
1131.46
53711.70
2803.89
55046.69
172.59
1130.72
5554.17
65.05
56177.31
141.96
53916.07
59617.42
1131.43
53462.18
5083.31
55044.50
112.60
452.71
452.79
53462.16
11220.56
53009.37
3679.26
52556.65
239.84
452.57
53914.73
12981.48
470.99
471.11
54386.72
4439.40
Counts vs. Deconvoluted Mass (amu)

FIG. 2B



x10 4
1.5
1.25
1
0.75
0.5
0.25
0
23000
23500
24000
24500
25000
25500
26000
26500
Counts vs. Deconvoluted Mass (amu)
23523.41
15323.68
1038.46
L0
24561.87
10799.22
L1
25783.82
312.80
26385.09
99.39
x10 4
3
2.5
2
1.5
1
0.5
0
50000
50500
51000
51500
52000
52500
53000
53500
54000
54500
55000
Counts vs. Deconvoluted Mass (amu)
1038.30
50527.16
12703.30
H0
1038.44
51565.46
20359.56
H1
1038.57
52603.90
21684.82
H2
53642.47
8784.89
H3
54683.21
131.39

FIG. 3



x10 4
4
3.5
3
2.5
2
1.5
1
0.5
0
1125.71
23523.23
27164.94
24648.94
27885.96
23846.46
237.33
25264.92
1467.47
25828.30
474.01
26391.63
262.55
L0
L1
23250 23500 23750 24000 24250 24500 24750 25000 25250 25500 25750 26000 26250 26500
Counts vs. Deconvoluted Mass (amu)
x10 4
4
3.5
3
2.5
2
1.5
1
0.5
0
1125.66
50526.80
16219.71
1125.62
51652.46
29575.68
1125.51
52718.09
28033.35
53903.59
9188.01
54882.35
114.73
H0
H1
H2
H3
50500 51000 51500 52000 52500 53000 53500 54000 54500 55000 55500
Counts vs. Deconvoluted Mass (amu)

FIG. 4



Pertuzumab-Compound (XI)
1.71
210
1.67
210
1.64
210
Pertuzumab-Compound (XI) + papain
1.67
210
1.73
210
1.53
210
neoDegrader P1
1.54
210
528.4
530.4
545.6
567.6
614.4
528.5
530.4
531.6
550.5
AU
Time
m/z
%

FIG. 5



BT-474
Anti-Proliferative Activity
Perfuzumab-Compound (X)
Rituximab-Compound (X)
% Viability
140
120
100
80
60
40
20
0
-13
-12
-11
-10
-9
Log Ab Conc. [M]

FIG. 6



NCI-N87
Anti-Proliferative Activity
Pertuzumab-Compound (X)
Rituximab-Compound (X)
% Viability
140
120
100
80
60
40
20
0
-13
-12
-11
-10
-9
Log Ab Conc. [M]

FIG. 7



BT-474
Anti-Proliferative Activity
Pertuzumab-Compound (XI)
Rituximab-Compound (XI)
% Viability
140
120
100
80
60
40
20
0
-13
-12
-11
-10
-9
Log Ab Conc. [M]

FIG. 8



NCI-H929
Anti-Proliferative Activity
Belantamab-Compound (XIV)
Synagis-Compound (XIV)
Belantamab
Compound (XIII)
% viability
140
120
100
80
60
40
20
0
-20
log conc. [M]
-4
-5
-6
-7
-8
-9
-10
-11

FIG. 9



Bystander Activity
2:1 ratio of SK-BR-3:Jurkat HiBiT
% Viability Jurkat HiBiT
140
120
100
80
60
40
-11
-10
-9
-8
-7
[payload]
Pertuzumab-Compound (X)
Jurkat HiBiT only
Pertuzumab-Compound (X)
SK-BR-3 + Jurkat HiBiT

FIG. 10



BT-474
Anti-Proliferative Activity
Pertuzumab-Compound (XVIII)
Pertuzumab-Compound (XI)
Rituximab-Compound (XVIII)
% viability
log Ab conc. [M]
140
120
100
80
60
40
20
0
-8
-9
-10
-11
-12
-13
-14

FIG. 11



BT-474
Anti-Proliferative Activity
% viability
log Ab conc. [M]
140
120
100
80
60
40
20
0
-14
-13
-12
-11
-10
-9
-8
Pertuzumab-Compound (XLI)
Pertuzumab-Compound (Ie)
Pertuzumab-Compound (XIX)
Pertuzumab-Compound (Ii)
Rituximab-Compound (XLI)
Rituximab-Compound (XIX)

FIG. 12



MV-4-11
Anti-Proliferative Activity
Gemtuzumab-Compound (XL)
Gemtuzumab-Compound (XL) + Gemtuzumab
Gemtuzumab-Compound (XL) + Trastuzumab
Compound 40-3
Gemtuzumab
Trastuzumab
% viability
140
120
100
80
60
40
20
0
-20
log concentration [M]
-12
-11
-10
-9
-8
-7
-6
-5

FIG. 13



untreated
1X10-8 M
1X10-9 M
1X10-10 M
1X10-11 M
1X10-12 M
1X10-9 M
1X10-10 M
BRD4
beta-actin
Gemtuzumab-Cmpd(XL)
Cmpd 40-3

FIG. 14



HCC1569
Vehicle
Pertuzumab-Compound (Ia) 3 mg/kg
Pertuzumab-Compound (Ia) 10 mg/kg
Pertuzumab-Compound (XI) 3 mg/kg
Pertuzumab-Compound (XI) 10 mg/kg
Tumor volume (mm3)
800
600
400
200
0
0
5
10
15
20
25
Time (days)

FIG. 15A



HCC1569
Vehicle
Pertuzumab-Compound (Ia) 3 mg/kg
Pertuzumab-Compound (Ia) 10 mg/kg
Pertuzumab-Compound (XI) 3 mg/kg
Pertuzumab-Compound (XI)10 mg/kg
Body weight (g)
30
28
26
24
22
0
5
10
15
20
25
Time (days)

FIG. 15B



x10^4
5.5
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
-0.5
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 10.5 11 11.5 12 12.5 13 13.5 14 14.5 15 15.5 16 16.5 17 17.5

FIG. 16




FIG. 17



3.43
217
4.23
244
1.0e+2
8.0e+1
6.0e+1
4.0e+1
2.0e+1
0.0
1.00
1.20
1.40
1.60
1.80
2.00
2.20
2.40
2.60
2.80
3.00
3.20
3.40
3.60
3.80
4.00
4.20
4.40

FIG. 18




FIG. 19A




FIG. 19B



Response[mAU]
x10¹
4
3
2
1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Retention time [min]
10.457
8.388
7.280

FIG. 20



mAU
400
300
200
100
0
1
2
3
4
5
6
3.183
Area: 164.946
4.429
Area: 643.177
5.162
Area: 244.126

FIG. 21



MV-4-11
Vehicle
BRD4 degrader 0.4 mg/kg QDx14
CD33-D antibody-Compound (XL) conjugate 10 mg/kg QWx2
ARV-825 10 mg/kg QDx14
Tumor volume (mm3)
1500
1000
500
0
0
5
10
15
20
25
Days

FIG. 22



Individual tumor volumes
Vehicle
BRD4 degrader 0.4 mg/kg QDx14
CD33-D antibody-Compound (XL) conjugate 10 mg/kg QWx2
ARV-825 10 mg/kg QDx14
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
20
25
Days

FIG. 23



MV-4-11
Vehicle
BRD4 degrader 0.4 mg/kg QDx14
CD33-D antibody-Compound (XL) conjugate 10 mg/kg QWx2
ARV-825 10 mg/kg QDx14
Body Weight (g)
40
30
20
10
0
0
5
10
15
20
25
Days

FIG. 24



CD79b-A antibody
CD79b-A antibody-Compound (XLIII) conjugate DAR 2
CD79b-A antibody-Compound (XLIII) conjugate DAR 3.2
CD79b-A antibody-Compound (XLIII) conjugate DAR 4.6
Synagis N297A
MFI
2000
1500
1000
500
0
-12
-11
-10
-9
-8
-7
-6
Log Concentration [M]

FIG. 25



CD79b-A antibody- Compound (XLIII) conjugate DAR 2
CD97b-A antibody
Unconjugated payload
[nM]
0
0.1
1
10
100
100
0.2
2
20
200
IRAK4
β-actin
CD79b-A antibody- Compound (XLIII) conjugate DAR 3.2
CD97b-A antibody
Unconjugated payload
[nM]
0
0.1
1
10
100
100
0.32
3.2
32
320
IRAK4
β-actin
CD79b-A antibody- Compound (XLIII) conjugate DAR 4.6
CD97b-A antibody
Unconjugated payload
[nM]
0
0.1
1
10
100
100
0.46
4.6
46
460
IRAK4
β-actin

FIG. 26



CD79b-A antibody-Compound
(XLIII) conjugate 10 nM
CD97b-A antibody [nM]
0
10
0.05
0.5
5
50
500
5000
0
IRAK4
β-actin

FIG. 27